Asset Details
Do you wish to reserve the book?
Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors
Do you wish to request the book?
Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors
2019
Overview
Immune checkpoint inhibitors (ICIs) have demonstrated significant clinical impact in improving overall survival of several malignancies associated with poor outcomes; however, only 20–40% of patients will show long-lasting survival. Further clarification of factors related to treatment response can support improvements in clinical outcome and guide the development of novel immune checkpoint therapies. In this article, we have provided an overview of the pharmacokinetic (PK) aspects related to current ICIs, which include target-mediated drug disposition and time-varying drug clearance. In response to the variation in treatment exposure of ICIs and the significant healthcare costs associated with these agents, arguments for both dose individualization and generalization are provided. We address important issues related to the efficacy and safety, the pharmacodynamics (PD), of ICIs, including exposure–response relationships related to clinical outcome. The unique PK and PD aspects of ICIs give rise to issues of confounding and suboptimal surrogate endpoints that complicate interpretation of exposure–response analysis. Biomarkers to identify patients benefiting from treatment with ICIs have been brought forward. However, validated biomarkers to monitor treatment response are currently lacking.
Publisher
Springer International Publishing,Springer Nature B.V,Springer Verlag
Subject
/ Antibodies, Monoclonal - pharmacokinetics
/ Antibodies, Monoclonal - therapeutic use
/ Antineoplastic Agents, Immunological - pharmacokinetics
/ Antineoplastic Agents, Immunological - pharmacology
/ Antineoplastic Agents, Immunological - therapeutic use
/ Cancer
/ Dose-Response Relationship, Drug
/ Dose-Response Relationship, Immunologic
/ Humans
/ Immune checkpoint inhibitors
/ Medicine
/ Melanoma
/ Oncology
/ Patients
/ Review
